Targeting calcium signaling pathways is an emerging area of interest in cancer therapy. If CACNA1S is found to play a significant role in cancer progression, it could become a target for novel therapies. Calcium channel blockers, which are currently used to treat cardiovascular diseases, might be repurposed or modified to specifically target cancer cells with abnormal calcium channel activity. Personalized medicine approaches could also be developed, where therapies are tailored based on the genetic profile of a patient's tumor, including the status of the CACNA1S gene.
